Tag : DaxibotulinumtoxinA

Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices
Fintech News

Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices

Fintech News Desk
Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, announced the signing of a definitive agreement to acquire Hint, Inc., a privately held company doing business under the name HintMD, which has created an integrated financial technology (fintech) platform......
1